Taiho-developed TAS-205 is designed to selectively inhibit hematopoietic prostaglandin D synthase (HPGDS), an enzyme related ...

Cargo will mark the latest in a string of acquisitions for the deal-hungry Concentra. So far this year, Concentra has signed ...

At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...

Headlands Research, a clinical trial site network with locations across the U.S. and Canada, has made its first step into the ...

Basilea already secured $29 million to develop its antifungals fosmanogepix and BAL2062, and the Swiss company announced this morning that it has confirmed it will also receive its next tranche of $39 ...

To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Following long-time chief José Almeida’s retirement earlier this year, Baxter announced it has officially named a new CEO. | ...